Treatment

Zyloric 300 mg Tablets clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
This study is testing a new medicine, S227928, alone and with an existing drug, venetoclax (Venclyxto), for adults with certain types of blood cancers, like AML, MDS/AML, or CMML, that have returned or not responded to previous treatment.
For: "Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome (MDS)/AML · or Chronic Myelomonocytic Leukemia (CMML)"
Finland · Germany · France